CardioVascular and Interventional Radiology

, Volume 36, Issue 4, pp 1151–1154 | Cite as

Everolimus-induced Pneumonitis after Drug-eluting Stent Implantation: A Case Report

  • Susumu Sakamoto
  • Naoshi Kikuchi
  • Atsuo Ichikawa
  • Go Sano
  • Keita Satoh
  • Keishi Sugino
  • Kazutoshi Isobe
  • Yujiro Takai
  • Kazutoshi Shibuya
  • Sakae Homma
Case Report

Abstract

Despite the wide use of everolimus as an antineoplastic coating agent for coronary stents to reduce the rate of restenosis, little is known about the health hazards of everolimus-eluting stents (EES). We describe a case of pneumonitis that developed 2 months after EES implantation for angina. Lung pathology demonstrated an organizing pneumonia pattern that responded to corticosteroid therapy. Although the efficacy of EES for ischemic heart disease is well established, EES carries a risk of pneumonitis.

Keywords

Everolimus-eluting stent Organizing pneumonia Pneumonitis 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Howard JE, Murat TR, Richard D et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847–858CrossRefGoogle Scholar
  2. 2.
    Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456PubMedCrossRefGoogle Scholar
  3. 3.
    Stone GW, Midei M, Newman W et al (2008) Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299:1903–1913PubMedCrossRefGoogle Scholar
  4. 4.
    White DA, Schwartz LH, Dimitrijevic S et al (2009) Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 4:1357–1363PubMedCrossRefGoogle Scholar
  5. 5.
    White DA, Camus P, Endo M et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396–403PubMedCrossRefGoogle Scholar
  6. 6.
    Frija J, Joly D, Knebelmann B, Dusser D et al (2012) Everolimus-related organizing pneumonia: a report establishing causality. Invest New Drugs 30:1244–1247PubMedCrossRefGoogle Scholar
  7. 7.
    Carreño CA, Gadea M (2007) Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation. Transplant Proc 39:505–594CrossRefGoogle Scholar
  8. 8.
    Champion L, Stern M, Israel-Biet D et al (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144:505–509PubMedCrossRefGoogle Scholar
  9. 9.
    Kato K, Fukuda S, Tetsuo Fujimaki T et al (2009) Paclitaxel-induced interstitial pneumonia after drug-eluting stent implantation: report of a fatal case. Inter Med 48:911–913CrossRefGoogle Scholar
  10. 10.
    Fujimaki T, Kato K, Fukuda S et al (2011) Acute interstitial pneumonitis after implantation of paclitaxel-eluting stents: a report of two fatal cases. Int J Cardiol 148:21–24CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2012

Authors and Affiliations

  • Susumu Sakamoto
    • 1
  • Naoshi Kikuchi
    • 1
  • Atsuo Ichikawa
    • 1
  • Go Sano
    • 1
  • Keita Satoh
    • 1
  • Keishi Sugino
    • 1
  • Kazutoshi Isobe
    • 1
  • Yujiro Takai
    • 1
  • Kazutoshi Shibuya
    • 2
  • Sakae Homma
    • 1
  1. 1.Department of Respiratory MedicineToho University School of MedicineTokyoJapan
  2. 2.Department of PathologyToho University School of MedicineTokyoJapan

Personalised recommendations